BCD-245 is a monoclonal antibody, an originator investigational product for human use being developed for the treatment of neuroblastoma.
A monoclonal antibody is a protein created by scientists in the laboratory, which is equivalent to natural immune system antibodies and designed to bind to a specific target in the human body1.
BCD-245 binds specifically to GD2 (disialoganglioside 2) found in large quantities on the surface of neuroblastoma cells2. The binding of BCD-245 to GD2 allows the body to detect and destroy tumor cells.
Preclinical trials in animals confirmed the safety and antitumor effects of BCD-245. The investigational product has not been previously used for the treatment of humans, so its side effects are currently unknown.
In the clinical trial, BCD-245 is administered intravenously. The research physician closely monitors patients’ health during treatment and will take all necessary actions to treat adverse events if they occur. All patients are given potent analgesics (painkillers) before the administration of BCD-245 to decrease the risk of pain.
- Breedveld FC. Therapeutic monoclonal antibodies. The Lancet. 2000;355(9205):735-40.
- Furman WL. Monoclonal Antibody Therapies for High Risk Neuroblastoma. Biologics. 2021 Jun 9;15:205-219. doi: 10.2147/BTT.S267278. PMID: 34135571; PMCID: PMC8200163.
This section of the website contains information about an unauthorized investigational medicinal product for medical use.